358 related articles for article (PubMed ID: 33643696)
1. Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers.
Masemann D; Meissner R; Schied T; Lichty BD; Rapp UR; Wixler V; Ludwig S
Oncoimmunology; 2021 Feb; 10(1):1885778. PubMed ID: 33643696
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.
Masemann D; Köther K; Kuhlencord M; Varga G; Roth J; Lichty BD; Rapp UR; Wixler V; Ludwig S
Oncoimmunology; 2018; 7(5):e1423171. PubMed ID: 29721377
[TBL] [Abstract][Full Text] [Related]
3. PD-1 IC Inhibition Synergistically Improves Influenza A Virus-Mediated Oncolysis of Metastatic Pulmonary Melanoma.
Sitnik S; Masemann D; Leite Dantas R; Wixler V; Ludwig S
Mol Ther Oncolytics; 2020 Jun; 17():190-204. PubMed ID: 32346609
[TBL] [Abstract][Full Text] [Related]
4. The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors.
Wang G; Cao J; Gui M; Huang P; Zhang L; Qi R; Chen R; Lin L; Han Q; Lin Y; Chen T; He P; Ma J; Fu R; Hong J; Wu Q; Yu H; Chen J; Huang C; Zhang T; Yuan Q; Zhang J; Chen Y; Xia N
J Exp Clin Cancer Res; 2023 Oct; 42(1):284. PubMed ID: 37891570
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option.
Ren Y; Miao JM; Wang YY; Fan Z; Kong XB; Yang L; Cheng G
Front Immunol; 2022; 13():961796. PubMed ID: 35911673
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
Hwang JK; Hong J; Yun CO
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
8. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
9. Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model.
Zhang H; Xie W; Zhang Y; Dong X; Liu C; Yi J; Zhang S; Wen C; Zheng L; Wang H
Cancer Gene Ther; 2022 May; 29(5):456-465. PubMed ID: 34561555
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
Ripp J; Hentzen S; Saeed A
Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
[TBL] [Abstract][Full Text] [Related]
11. Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting.
Clubb JHA; Kudling TV; Girych M; Haybout L; Pakola S; Hamdan F; Cervera-Carrascon V; Hemmes A; Grönberg-Vähä-Koskela S; Santos JM; Quixabeira DCA; Basnet S; Heiniö C; Arias V; Jirovec E; Kaptan S; Havunen R; Sorsa S; Erikat A; Schwartz J; Anttila M; Aro K; Viitala T; Vattulainen I; Cerullo V; Kanerva A; Hemminki A
Front Immunol; 2023; 14():1060540. PubMed ID: 36817448
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF; Taha Z; Janssen TJA; Petryk J; Boulton S; Alluqmani N; Jirovec A; Kassas O; Khan ST; Vallati S; Lee E; Huang BZ; Huh M; Pikor L; He X; Marius R; Austin B; Duong J; Pelin A; Neault S; Azad T; Breitbach CJ; Stojdl DF; Burgess MF; McComb S; Auer R; Diallo JS; Ilkow CS; Bell JC
Front Immunol; 2022; 13():1029269. PubMed ID: 36405739
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment.
Uche IK; Kousoulas KG; Rider PJF
Viruses; 2021 Jun; 13(7):. PubMed ID: 34206677
[TBL] [Abstract][Full Text] [Related]
15. Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.
Kagabu M; Yoshino N; Murakami K; Kawamura H; Sasaki Y; Muraki Y; Baba T
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768352
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. Swine pseudorabies virus attenuated vaccine reprograms the kidney cancer tumor microenvironment and synergizes with PD-1 blockade.
Gui M; Wu C; Qi R; Zeng Y; Huang P; Cao J; Chen T; Chen K; Lin L; Han Q; He P; Fu R; Wu Q; Yuan Q; Zhang T; Xia N; Wang G; Chen Y
J Med Virol; 2024 Apr; 96(4):e29568. PubMed ID: 38549430
[TBL] [Abstract][Full Text] [Related]
18. Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors.
Cui B; Song L; Wang Q; Li K; He Q; Wu X; Gao F; Liu M; An C; Gao Q; Hu C; Hao X; Dong F; Zhou J; Liu D; Song Z; Yan X; Zhang J; Bai Y; Mao Q; Yang X; Liang Z
Signal Transduct Target Ther; 2023 Sep; 8(1):366. PubMed ID: 37743418
[TBL] [Abstract][Full Text] [Related]
19. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar SR; Wang SJ; Thandoni A; Bommareddy PK; Newman JH; Marzo AL; Kuzel TM; Gupta V; Reiser J; Daniels P; Schiff D; Mitchell D; LeBoeuf NR; Simmons C; Goyal S; Lasfar A; Guevara-Patino JA; Haffty BG; Kaufman HL; Silk AW; Zloza A; Giurini EF
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37433716
[TBL] [Abstract][Full Text] [Related]
20. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
